Avid Bioservices (CDMO) Tops Q1 EPS by 2c, Revenues Beat; Offers FY20 Revenue Mid-Point Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Avid Bioservices Reports Financial Results for Second Quarter Fiscal 2020 and Recent Developments
December 9, 2019 4:05 PM EST-- Achieved Strong Second Quarter Revenue of $18.3 Million and Gross Margin of 18% --
-- Fiscal 2020 Projected Revenue of $64 to $67 Million Reaffirmed --
-- Launched Expanded Process Development Facility and Services --
TUSTIN, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (NASDAQ: CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced financial results for the... More
